Receptor editing and receptor revision in rheumatic autoimmune diseases

Trends in Immunology

Volumn 29, Issue 3, 2008, Pages 103-109

  Zouali, Moncef ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR;

ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL FUNCTION; EPIGENETICS; HEREDITY; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR MECHANICS; PROTEIN FUNCTION; RECEPTOR EDITING; RHEUMATIC DISEASE;

ANIMALS; AUTOIMMUNE DISEASES; GENE REARRANGEMENT, B-LYMPHOCYTE; HUMANS; MICE; RECEPTORS, ANTIGEN, B-CELL; RHEUMATIC DISEASES;

EID: 39849111456     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2007.12.004     Document Type: Article

References (62)

1. Viau M., and Zouali M. B-lymphocytes, innate immunity, and autoimmunity. Clin. Immunol. 114 (2005) 17-26
2. Hasler P., and Zouali M. B lymphocytes as therapeutic targets in systemic lupus erythematosus. Expert Opin. Ther. Targets 10 (2006) 803-815
3. Nemazee D., and Buerki K. Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 8039-8043
4. Nossal G.J., and Pike B.L. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 1602-1606
5. Gay D., et al. Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177 (1993) 999-1008
6. Tiegs S.L., et al. Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177 (1993) 1009-1020
7. Nemazee D., and Weigert M. Revising B cell receptors. J. Exp. Med. 191 (2000) 1813-1817
8. Lang J., et al. B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen. J. Exp. Med. 184 (1996) 1685-1697
9. Li Y., et al. Autoreactive B cells in the marginal zone that express dual receptors. J. Exp. Med. 195 (2002) 181-188
10. Liu S., et al. Receptor editing can lead to allelic inclusion and development of B cells that retain antibodies reacting with high avidity autoantigens. J. Immunol. 175 (2005) 5067-5076
11. Huang H., et al. Induction of tolerance in arthritogenic B cells with receptors of differing affinity for self-antigen. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3734-3739
12. Casellas R., et al. Igκ allelic inclusion is a consequence of receptor editing. J. Exp. Med. 204 (2007) 153-160
13. Bensimon C., et al. Human lupus anti-DNA autoantibodies undergo essentially primary V κ gene rearrangements. EMBO J. 13 (1994) 2951-2962
14. Suzuki N., et al. Characterization of a germline Vκ gene encoding cationic anti-DNA antibody and role of receptor editing for development of the autoantibody in patients with systemic lupus erythematosus. J. Clin. Invest. 98 (1996) 1843-1850
15. Radic M.Z., and Zouali M. Receptor editing, immune diversification and self-tolerance. Immunity 5 (1996) 505-511
16. Yurasov S., et al. Persistent expression of autoantibodies in SLE patients in remission. J. Exp. Med. 203 (2006) 2255-2261
17. Lamoureux J.L., et al. Reduced receptor editing in lupus-prone MRL/lpr mice. J. Exp. Med. 204 (2007) 2853-2864
18. Samuels J., et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201 (2005) 1659-1667
19. Faber C., et al. Differential expression patterns of recombination-activating genes in individual mature B cells in juvenile idiopathic arthritis. Ann. Rheum. Dis. 65 (2006) 1351-1356
20. Li H., et al. Editors and editing of anti-DNA receptors. Immunity 15 (2001) 947-957
21. Meffre E., et al. Antigen receptor engagement turns off the V(D)J recombination machinery in human tonsil B cells. J. Exp. Med. 188 (1998) 765-772
22. Hertz M., et al. V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling. Nature 394 (1998) 292-295
23. Dorner T., et al. Immunoglobulin κ chain receptor editing in systemic lupus erythematosus. J. Clin. Invest. 102 (1998) 688-694
24. Kouskoff V., et al. B cell receptor expression level determines the fate of developing B lymphocytes: receptor editing versus selection. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7435-7439
25. Han S., et al. V(D)J recombinase activity in a subset of germinal center B lymphocytes. Science 278 (1997) 301-305
26. Cascalho M., et al. VH gene replacement in hyperselected B cells of the quasimonoclonal mouse. J. Immunol. 159 (1997) 5795-5801
27. Lopez-Macias C., et al. Secondary rearrangements and hypermutation generate sufficient B cell diversity to mount protective antiviral immunoglobulin responses. J. Exp. Med. 189 (1999) 1791-1798
28. Giachino C., et al. Re-expression of RAG-1 and RAG-2 genes and evidence for secondary rearrangements in human germinal center B lymphocytes. Eur. J. Immunol. 28 (1998) 3506-3513
29. Girschick H.J., et al. RAG1 and RAG2 expression by B cell subsets from human tonsil and peripheral blood. J. Immunol. 166 (2001) 377-386
30. Hillion S., et al. Expression of RAGs in peripheral B cells outside germinal centers is associated with the expression of CD5. J. Immunol. 174 (2005) 5553-5561
31. Wilson P.C., et al. Receptor revision of immunoglobulin heavy chain variable region genes in normal human B lymphocytes. J. Exp. Med. 191 (2000) 1881-1894
32. Brard F., et al. Somatic mutation and light chain rearrangement generate autoimmunity in anti-single-stranded DNA transgenic MRL/lpr mice. J. Exp. Med. 190 (1999) 691-704
33. Kouskoff V., et al. Organ-specific disease provoked by systemic autoimmunity. Cell 87 (1996) 811-822
34. Qin X.F., et al. Secondary V(D)J recombination in B-1 cells. Nature 397 (1999) 355-359
35. Wakui M., et al. Genetic dissection of lupus pathogenesis: Sle3/5 impacts IgH CDR3 sequences, somatic mutations, and receptor editing. J. Immunol. 173 (2004) 7368-7376
36. Klonowski K.D., and Monestier M. Heavy chain revision in MRL mice: a potential mechanism for the development of autoreactive B cell precursors. J. Immunol. 165 (2000) 4487-4493
37. Girschick H.J., et al. Expression of recombination activating genes 1 and 2 in peripheral B cells of patients with systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 1255-1263
38. - B cells of patients with childhood systemic lupus erythematosus. Ann. Rheum. Dis. 65 (2006) 482-487
39. Meffre E., et al. Circulating human B cells that express surrogate light chains and edited receptors. Nat. Immunol. 1 (2000) 207-213
40. Chen C., et al. Editing disease-associated autoantibodies. Immunity 6 (1997) 97-105
41. Xu H., et al. Regulation of anti-DNA B cells in recombination-activating gene-deficient mice. J. Exp. Med. 188 (1998) 1247-1254
42. Erikson J., et al. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 349 (1991) 331-334
43. Goodnow C.C., et al. Induction of self-tolerance in mature peripheral B lymphocytes. Nature 342 (1989) 385-391
44. Chen C., et al. Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing. Immunity 3 (1995) 747-755
45. Itoh K., et al. Immunoglobulin heavy chain variable region gene replacement as a mechanism for receptor revision in rheumatoid arthritis synovial tissue B lymphocytes. J. Exp. Med. 192 (2000) 1151-1164
46. Buhl A.M., and Cambier J.C. Co-receptor and accessory regulation of B-cell antigen receptor signal transduction. Immunol. Rev. 160 (1997) 127-138
47. Treisman R. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 8 (1996) 205-215
48. Richards J.D., et al. Inhibition of the MEK/ERK signaling pathway blocks a subset of B cell responses to antigen. J. Immunol. 166 (2001) 3855-3864
49. Verkoczy L., et al. A role for nuclear factor κ B/rel transcription factors in the regulation of the recombinase activator genes. Immunity 22 (2005) 519-531
50. Stork P.J. Directing NGF's actions: it's a Rap. Nat. Cell Biol. 7 (2005) 338-339
51. Ishida D., et al. Rap1 signal controls B cell receptor repertoire and generation of self-reactive B1a cells. Immunity 24 (2006) 417-427
52. Liang Z., et al. Molecular signatures of anti-nuclear antibodies: contributions of specific light chain residues and a novel New Zealand Black V κ 1 germline gene. J. Immunol. 171 (2003) 3886-3894
53. Mazari L., et al. Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 6317-6322
54. Sutherland C.L., et al. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J. Immunol. 157 (1996) 3381-3390
55. Healy J.I., et al. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 6 (1997) 419-428
56. Benschop R.J., et al. Activation and anergy in bone marrow B cells of a novel immunoglobulin transgenic mouse that is both hapten specific and autoreactive. Immunity 14 (2001) 33-43
57. Zouali M., et al. Quantitative clonal analysis of the B cell repertoire in human lupus. Cell. Immunol. 133 (1991) 161-177
58. Wardemann H., et al. Predominant autoantibody production by early human B cell precursors. Science 301 (2003) 1374-1377
59. Yurasov S., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201 (2005) 703-711
60. Kumar K.R., et al. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science 312 (2006) 1665-1669
61. Liu Y., et al. Lupus susceptibility genes may breach tolerance to DNA by impairing receptor editing of nuclear antigen-reactive B cells. J. Immunol. 179 (2007) 1340-1352
62. Feinberg A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 447 (2007) 433-440